205
Participants
Start Date
March 4, 2011
Primary Completion Date
July 1, 2013
Study Completion Date
March 11, 2015
OSI-906
Tablet administered with food and with up to 200 mL of water
erlotinib
Tablet administered at least 2 hours after food with up to 200 mL of water
placebo
Tablet administered at least 2 hours after food with up to 200 mL of water
Site DE49014, Berlin
Site DE49003, Großhansdorf
Site DE49010, Lübeck
Site US10010, Winston-Salem
Site US10004, Greensboro
Site US10002, Albany
Site US10007, Jacksonville
Site DE49005, Minden
Site DE49015, Kassel
Site DE49006, Immenhausen
Site US10001, Port Saint Lucie
Site DE49011, Dortmund
Site DE49008, Cologne
Site DE49013, Mainz
Site DE49002, Hemer
Site US10008, Chicago
Site DE49009, Homburg/Saar
Site DE49001, Heidelberg
Site DE49012, Karlsruhe
Site RU70007, Saint Petersburg
Site RU70009, Saint Petersburg
Site RU70011, Saint Petersburg
Site RO40006, Craiova
Site RO40004, Hunedoara
Site RO40002, Cluj-Napoca
Site RO40003, Cluj-Napoca
Site RU70010, Kazan'
Site RU70002, Chelaybinsk
Site RO40001, Baia Mare
Site RO40007, Brasov
Site RO40005, Alba Iulia
Site US10011, Scarborough
Site BR55005, Barretos
Site BR55004, Brasília
Site BR55015, Cachoeiro de Itapemirim
Site BR55011, Florianópolis
Site BR55003, Fortaleza
Site BR55016, Goiânia
Site BR55006, Ijuí
Site BR55001, Itajaí
Site BR55008, Piracicaba
Site BR55013, Porto Alegre
Site BR55014, Porto Alegre
Site BR55012, Ribeirão Preto
Site BR55002, Rio de Janeiro
Site BR55007, São Paulo
Site CA11001, Oshawa
Site CA11004, Ottawa
Site CA11006, Toronto
Site CA11002, Toronto
Site PL48002, Elblag
Site PL48005, Szczecin
Site PL48008, Torun
Site PL48006, Wroclaw
Site KR82007, Busan
Site KR82006, Hwasun
Site KR82008, Incheon
Site KR82004, Seongnam-si
Site KR82003, Seoul
Site KR82005, Seoul
Site KR82002, Seoul
Site KR82001, Suwon
Site GB44007, Bristol
Site GB44006, Dundee
Site GB44003, Leeds
Site GB44002, Leicester
Site GB44005, London
Site GB44001, Manchester
Site GB44004, Southampton
Lead Sponsor
Astellas Pharma Inc
INDUSTRY